2024 has been a truly exciting year for us, marked by dedication, innovation, and meaningful impact. Thanks to the relentless efforts of our trial team, we’ve achieved some remarkable milestones:
- A 41% increase in the number of new clinical trials opened
- A 12% rise in the number of patients treated
- A broad research focus including breast, gastrointestinal, genitourinary, gynaecological, lung, and sarcoma trials.
With 2025 already taking shape, we pause to acknowledge the progress and accomplishments of 2024.
